Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 18/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30104276 | 1.00 | AR (1.00) | AR | |
| SCHEMBL30104280 | 1.00 | AR (1.00) | AR | |
| SCHEMBL13482465 | 1.00 | AR (1.00) | AR | |
| SCHEMBL23844279 | 1.00 | AR (1.00) | AR | |
| SCHEMBL3194740 | 1.00 | AR (1.00) | AR | |
| SCHEMBL23844357 | 1.00 | AR (1.00) | AR | |
| SCHEMBL23844361 | 1.00 | AR (1.00) | AR | |
| SCHEMBL23844362 | 1.00 | AR (1.00) | AR | |
| SCHEMBL3180762 | 1.00 | AR (1.00) | AR | |
| SCHEMBL13481660 | 1.00 | AR (1.00) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1854798-A2 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | Bristol-Myers Squibb Company (US) | 2007-11-14 | — | — | EP | claimed |
| US-12552806-B2 | Androgen receptor regulation by small molecule enantiomers | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2026-02-17 | — | — | US | disclosed |
| US-20240208985-A2 | ANDROGEN RECEPTOR REGULATION BY SMALL MOLECULE ENANTIOMERS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240208985-A2 | ANDROGEN RECEPTOR REGULATION BY SMALL MOLECULE ENANTIOMERS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2024-06-27 | — | — | US | disclosed |
| US-20230133119-A1 | ANDROGEN RECEPTOR REGULATION BY SMALL MOLECULE ENANTIOMERS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230133119-A1 | ANDROGEN RECEPTOR REGULATION BY SMALL MOLECULE ENANTIOMERS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230133119-A1 | ANDROGEN RECEPTOR REGULATION BY SMALL MOLECULE ENANTIOMERS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2023-05-04 | — | — | US | disclosed |
| WO-2021189051-A1 | ANDROGEN RECEPTOR REGULATION BY SMALL MOLECULE ENANTIOMERS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2021-09-23 | — | — | WO | disclosed |
| US-7517904-B2 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-14 | — | — | US | disclosed |
| US-7470797-B2 | Fused heterocyclic imido and amido compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-30 | — | — | US | disclosed |
| US-20080214643-A1 | FUSED HETEROCYCLIC SUCCINIMIDE COMPOUNDS AND ANALOGS THEREOF, MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2008-09-04 | — | — | US | disclosed |
| EP-1854798-A2 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | Bristol-Myers Squibb Company (US) | 2007-11-14 | — | — | EP | disclosed |
| US-20060223832-A1 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | SALVATI MARK E | 2006-10-05 | — | — | US | disclosed |
| US-20050272799-A1 | Fused Heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | SALVATI MARK E | 2005-12-08 | — | — | US | disclosed |
| US-20050192253-A1 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | SALVATI MARK E (US) | 2005-09-01 | — | — | US | disclosed |
| US-20040077605-A1 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077605-A1 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, NCOA3, NR5A2 | AR 33/4885 |
| US-20240208985-A2 | ANDROGEN RECEPTOR REGULATION BY SMALL MOLECULE ENANTIOMERS | AR, SHBG, NR5A1 | AR 1/4885 |
| US-20060223832-A1 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, NCOA3, NR5A2 | AR 33/4885 |
| US-20050192253-A1 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, NCOA3, NR5A2 | AR 33/4885 |
| US-20230133119-A1 | ANDROGEN RECEPTOR REGULATION BY SMALL MOLECULE ENANTIOMERS | AR, SHBG, NR5A1 | AR 1/4885 |
| US-20050272799-A1 | Fused Heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, NCOA3, NR5A2 | AR 33/4885 |
| US-20080214643-A1 | FUSED HETEROCYCLIC SUCCINIMIDE COMPOUNDS AND ANALOGS THEREOF, MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | NCOA1, NCOA3, NR5A2 | AR 33/4885 |
| US-12552806-B2 | Androgen receptor regulation by small molecule enantiomers | AR, ADRA1D, ADRA1A | AR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.